Cunningham, TJ, Oetinger, M, Blankenhorn EP, Greenstein, JI.Secreted Phospholipase A2 activity in experimental allergic encephalomyelitis and multiple sclerosis. Journal of Neuroinflammation 2006; 3:26
Herndon RM, Greenstein JI. Multiple Sclerosis and Demyelinating Diseases. In: Herndon RM. (Ed) Handbook of Neurologic Rating Scales. 2nd Ed. 2007.
Greenstein JI. Current concepts of the cellular and molecular pathophysiology of Multiple Sclerosis. Developmental Neurobiology 2008; 67:1248-1265.
Cunningham, TJ, Greenstein, JI et al. Uncompetitive Phospholipase A2 inhibition by CHEC sequences including oral treatment of experimental autoimmune myeloencephalitis. The Open Enzyme Inhibition Journal 2009; 2:1-7.
Greenstein JI. Oral disease modifying therapy for MS: Important considerations. Practical Neurology 2011; 10:36 41.
Greenstein JI. Immunemodulation induced by Natalizumab therapy in Multiple Sclerosis. Academy of Neurology Annual Meeting April, 2014
Greenstein JI, Cunningham TJ. Neuroprotective, Anti-inflammatory and Immune Tolerizing properties of peptides derived from Diffusion Survival Evasion Protein (DSEP)/Dermcidin. Academy of Neurology Annual Meeting April, 2014.
Message from Dr. Greenstein
Curing MS is my life’s work. As you know, MS not only changes the lives of those affected by it, but it also touches the lives of their families and friends. My mission in founding the Multiple Sclerosis Research Institute (“MSRI”) is to FIND the cause, STOP the progression and CURE the disease so that those with MS, as well as future generations, can enjoy a life free from its symptoms.